267 related articles for article (PubMed ID: 33310293)
41. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
42. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
43. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer.
Spanheimer PM; Carr JC; Thomas A; Sugg SL; Scott-Conner CE; Liao J; Weigel RJ
Am J Surg; 2013 Jul; 206(1):2-7. PubMed ID: 23375759
[TBL] [Abstract][Full Text] [Related]
44. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
[TBL] [Abstract][Full Text] [Related]
45. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
Meisel JL; Zhao J; Suo A; Zhang C; Wei Z; Taylor C; Aneja R; Krishnamurti U; Li Z; Nahta R; O'Regan R; Li X
Clin Breast Cancer; 2020 Feb; 20(1):19-24. PubMed ID: 31806448
[TBL] [Abstract][Full Text] [Related]
46. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends.
Graham PJ; Brar MS; Foster T; McCall M; Bouchard-Fortier A; Temple W; Quan ML
Ann Surg Oncol; 2015 Oct; 22(10):3376-82. PubMed ID: 26202561
[TBL] [Abstract][Full Text] [Related]
47. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
[TBL] [Abstract][Full Text] [Related]
48. Are breast conservation treatment rates optimized for Asian women with symptomatic malignancies?
Tan MPC; Sitoh YY
ANZ J Surg; 2019 May; 89(5):529-535. PubMed ID: 30972960
[TBL] [Abstract][Full Text] [Related]
49. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
Mittendorf EA; Buchholz TA; Tucker SL; Meric-Bernstam F; Kuerer HM; Gonzalez-Angulo AM; Bedrosian I; Babiera GV; Hoffman K; Yi M; Ross MI; Hortobagyi GN; Hunt KK
Ann Surg; 2013 Feb; 257(2):173-9. PubMed ID: 23291658
[TBL] [Abstract][Full Text] [Related]
50. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
[TBL] [Abstract][Full Text] [Related]
51. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.
Volders JH; Negenborn VL; Spronk PE; Krekel NMA; Schoonmade LJ; Meijer S; Rubio IT; van den Tol MP
Breast Cancer Res Treat; 2018 Feb; 168(1):1-12. PubMed ID: 29214416
[TBL] [Abstract][Full Text] [Related]
52. Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer.
Hage AN; Capriccioso C; Brennan J; Heiden B; Zheutlin A; Sabel MS
J Surg Oncol; 2017 Nov; 116(6):665-670. PubMed ID: 28672101
[TBL] [Abstract][Full Text] [Related]
53. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
[TBL] [Abstract][Full Text] [Related]
56. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
[TBL] [Abstract][Full Text] [Related]
57. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
58. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
59. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
[TBL] [Abstract][Full Text] [Related]
60. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
